orapeutic chicago midwinter meeting

(Houston, TX) Forward Science received FDA Clearance for Orapeutic™, a non-opioid oral pain relief gel in December of 2019. This all natural, oral wound dressing will now be released at the Chicago Midwinter Meeting in February 2020.

Forward Science is a MedTech company that operates R&D, its quality system, manufacturing, sales and support all from its worldwide headquarters in Houston, TX. The company’s flagship product, OralID, received FDA Clearance in March of 2013 and has since revolutionized the way clinicians screen for early stage oral cancer. In 2016 the company launched SalivaMAX in efforts to provide patients with a clinically proven option to mitigate the effects of xerostomia and mucositis. Orapeutic, the company’s third FDA cleared product, has been developed to fight the current opioid epidemic that the healthcare industry is facing today.

“The attendees at Chicago Midwinter are dedicated clinicians who value high quality products and elite patient care,” says Forward Science’s National Sales Director, Cassie Wilson. “Our R&D team developed Orapeutic not only to meet market demands, but to exceed clinical expectations—for this reason we chose to release this life changing product to the exceptional group at the Chicago Midwinter Meeting.”

With the recent concerns surrounding opioid prescription in the dental industry, Forward Science has been working on a non-drug option to manage oral pain, and Orapeutic will do just that. Dentists and oral surgeons are by far the majority of prescribers for opioids to people ages 10-19. This is a critical age range in which the still developing brain is particularly susceptible to addiction. (Journal of American Medical Association, 2011). “The opioid epidemic has forced the dental industry to re-evaluate our approach to pain management to ensure we're providing holistic care to our patients and preventing adverse outcomes from our prescribing habit” explains Forward Science’s Director of Training and Education, Ellen Myers, RDH, BS. “We are extremely proud to release this all-natural, non-opioid product that provides patients with adequate pain relief and protection. We truly believe this product will change lives and look forward to hearing feedback at the Chicago Midwinter Meeting.”

If you are attending Chicago Midwinter Meeting and are interested in learning more about Orapeutic, Ellen will be presenting at the new product showcase on Thursday, February 20th from 1-4pm. For more information you can visit our website.

FDA Indications for Orapeutic:

OrapeuticTM Oral Pain Gel manages the pain of oral wounds, mouth sores, injuries and ulcers of the oral mucosa. It adheres to the oral tissue and forms a protective barrier between the wound and further prevents irritation and contamination. Orapeutic Oral Pain Gel also maintains a moist wound environment.

About Forward Science

Forward Science is a privately held MedTech company based in Houston, Texas. OralID, Forward Science’s flagship product, is an award-winning oral cancer screening device that allows clinicians to visualize abnormalities that may not be seen under traditional white light examinations. With the success of OralID, Forward Science continued to focus on moving science forward in the oral healthcare industry by launching advanced diagnostic testing products (CytID, hpvID, phID, PathID) along with treatment options (SalivaMAX and SalivaCAINE). In addition to developing proprietary, state-of-the-art products, Forward Science has partnered with industry leaders to provide new and effective solutions to the dental community. Forward Science designs, develops, and manufactures their products in-house, ensuring the highest quality of standards coupled with superior customer service. Forward Science has quickly evolved into the industry leader for providing oral healthcare products worldwide.

To learn more about any of Forward Science’s products, please visit www.ForwardScience.com or call 855-696-7254.